Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Inthepezon Aug 19, 2021 12:10pm
126 Views
Post# 33730702

RE:RE:Otenaproxesul and COVID-19 Data

RE:RE:Otenaproxesul and COVID-19 DataI listened to the AGM meeting and it brought up great info. I’m overall bullish.While there will be a 12month delay for ph3, I’m betting we bounce to the $2.5-3 range by December.

Partnership negotiations will resume after the investigation of the AME is complete (which will take 5 weeks according to Dan and Stauffer). 

A good take away was Stauffer and Dan mentioning that H2S provides a protective effect on the liver much like the GI effects. And that the ALT elevation is not a serious issue but is a class issue of the drug. Stauffer hammered home, Te elevation is not a serious event. 

They also mentioned their naproxen different from commercial naproxen, more stable not up and down like commercial naproxen - so the stability provides protective effective protection,  where most of their work is centered around , they think they are close to a dose level that is effective.

overall bullish. Big F***k you to the FUD fairies esp rarbar99 aka Yukonjizz face
<< Previous
Bullboard Posts
Next >>